EXOZYMES INC. Professional Fees
EXOZYMES INC. (EXOZ) reported Professional Fees of $214.88 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2026-08-13
- EXOZYMES INC. professional fees for the quarter ending 2026-06-30 was $214.88K, a 41.76% decline year-over-year.
- EXOZYMES INC. professional fees for the quarter ending 2026-03-31 was $277.68K, a 47.83% decline year-over-year.
- EXOZYMES INC. professional fees for the quarter ending 2025-12-31 was $302.58K, a 13.85% decline year-over-year.
- EXOZYMES INC. professional fees for the quarter ending 2025-09-30 was $237.92K, a 11.73% decline year-over-year.
- EXOZYMES INC. professional fees for fiscal 2025 was $1.44M, a 23.51% increase from fiscal 2024.
- EXOZYMES INC. professional fees for fiscal 2024 was $1.17M, a 167.51% increase from fiscal 2023.
- EXOZYMES INC. professional fees for fiscal 2023 was $436.34K.
| Period end | Professional Fees 3 month | Professional Fees 6 month | Professional Fees 9 month | Professional Fees 12 month |
|---|---|---|---|---|
| 2026-06-30 | $214.88K 10-Q · filed 2026-08-13 | $492.56K 10-Q · filed 2026-08-13 | $795.14K derived: sum of 3 quarters · filed 2026-08-13 | $1.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $277.68K 10-Q · filed 2026-05-14 | $580.25K derived: sum of 2 quarters · filed 2026-05-14 | $818.17K derived: sum of 3 quarters · filed 2026-05-14 | $1.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $302.58K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $540.49K derived: sum of 2 quarters · filed 2026-03-30 | $909.42K derived: sum of 3 quarters · filed 2026-08-13 | $1.44M 10-K · filed 2026-03-30 |
| 2025-09-30 | $237.92K 10-Q · filed 2025-11-13 | $606.85K derived: sum of 2 quarters · filed 2026-08-13 | $1.14M 10-Q · filed 2025-11-13 | $1.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $368.93K 10-Q · filed 2026-08-13 | $901.17K 10-Q · filed 2026-08-13 | $1.25M derived: sum of 3 quarters · filed 2026-08-13 | $1.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $532.24K 10-Q · filed 2026-05-14 | $883.48K derived: sum of 2 quarters · filed 2026-05-14 | $1.15M derived: sum of 3 quarters · filed 2026-05-14 | $1.44M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $351.24K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $620.78K derived: sum of 2 quarters · filed 2026-03-30 | $910.69K derived: sum of 3 quarters · filed 2026-03-30 | $1.17M 10-K · filed 2026-03-30 |
| 2024-09-30 | $269.54K 10-Q · filed 2025-11-13 | $559.45K derived: sum of 2 quarters · filed 2025-11-13 | $816.01K 10-Q · filed 2025-11-13 | $951.10K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $289.90K 10-Q · filed 2025-08-12 | $546.47K 10-Q · filed 2025-08-12 | $681.56K derived: sum of 3 quarters · filed 2025-08-12 | $774.07K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $256.56K 10-Q · filed 2025-05-12 | $391.66K derived: sum of 2 quarters · filed 2025-05-12 | $484.17K derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $135.09K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $227.60K derived: sum of 2 quarters · filed 2025-03-31 | $436.34K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $92.51K 10-Q · filed 2024-11-12 | $301.24K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |